Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 12/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.61 |
| ▸ | CYP2C8 | P10632 | 4/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.61 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.37 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.37 |
| ▸ | STAT3 | P40763 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL934797 | 0.89 | PTGDR2 (0.60) | PTGDR2CYP2C19CYP2C8CYP2C9MAPK8 | |
| SCHEMBL934625 | 0.88 | PTGDR2 (0.60) | PTGDR2CYP2C19CYP2C8CYP2C9LTB4R2 | |
| SCHEMBL933439 | 0.85 | PTGDR2 (0.62) | PTGDR2CYP2C19CYP2C8CYP2C9LTB4R2 | |
| SCHEMBL934773 | 0.84 | PTGDR2 (0.64) | PTGDR2CYP2C19CYP2C8CYP2C9STAT3 | |
| SCHEMBL935120 | 0.82 | PTGDR2 (0.62) | PTGDR2CYP2C19CYP2C8CYP2C9 | |
| SCHEMBL934007 | 0.80 | PTGDR2 (0.65) | PTGDR2CYP2C19CYP2C8CYP2C9 | |
| SCHEMBL935294 | 0.80 | PTGDR2 (0.63) | PTGDR2CYP2C19CYP2C8CYP2C9STAT3 | |
| SCHEMBL2681123 | 0.78 | PTGDR2 (0.51) | PTGDR2CYP2C19CYP2C8CYP2C9LTB4R2 | |
| SCHEMBL933949 | 0.78 | PTGDR2 (0.64) | PTGDR2CYP2C19CYP2C8CYP2C9 | |
| SCHEMBL935225 | 0.78 | PTGDR2 (0.62) | PTGDR2CYP2C19CYP2C8CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2454243-A2 | TETRAZOLE DERIVATIVES | Merck Serono SA (CH) | 2012-05-23 | — | — | EP | disclosed |
| US-20120115869-A1 | TETRAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2012-05-10 | — | — | US | disclosed |
| WO-2011006935-A2 | TETRAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115869-A1 | TETRAZOLE DERIVATIVES | TSLP, IL5, CMA1 | PTGDR2 548/4885CYP2C19 18/4885CYP2C8 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.